Partnership Announcement: New Malaria Prevention Drug Collaboration with Nagasaki University, National Institute of Infectious Diseases, and MMV, Backed by GHIT Fund
Shionogi, in collaboration with Nagasaki University (Administrative Office: Nagasaki; President: Takeshi Nagayasu, M.D., Ph.D.), the National Institute of Infectious Diseases (Head Office: Shinjuku-ku, Tokyo; Director: Takashi Wakita), and the non-profit…
BeiGene Unveils Q1 2024 Financial Performance and Business Developments
BeiGene, a leading global oncology firm, has unveiled its first-quarter 2024 results alongside significant business updates. John V. Oyler, Co-Founder, Chairman, and CEO at BeiGene, expressed satisfaction with the robust…
Jeffrey Kindler and Alfonso Zulueta Appointed as Independent Directors to Lupin’s Board
Lupin, a leading pharmaceutical company, has recently welcomed two distinguished individuals, Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta, to its Board as Independent Directors. Mr. Kindler boasts an illustrious…
CRISPR Therapeutics’ Business Update and First Quarter 2024 Financial Report
CRISPR Therapeutics (Nasdaq: CRSP), a company dedicated to pioneering gene-based medicines for severe illnesses, has unveiled its financial performance for the first quarter ending March 31, 2024. CEO and Chairman…
Revolution Medicines Unveils Q1 2024 Financial Report and Corporate Advancements Update
Revolution Medicines, Inc. (Nasdaq: RVMD), a company focused on developing targeted therapies for patients with RAS-addicted cancers, has disclosed its financial results for the quarter ending March 31, 2024, alongside…
Vertex Unveils Financial Performance for Q1 2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced its consolidated financial performance for the first quarter ended March 31, 2024, while reaffirming its full-year 2024 financial outlook. Reshma Kewalramani, M.D., Chief Executive…
AstraZeneca Finalizes Equity Investment Deal with Cellectis
AstraZeneca has confirmed the successful conclusion of its equity investment agreement with Cellectis, a clinical-stage biotech firm. The investment, along with a research collaboration deal unveiled in November 2023, aims…
Soleo Health Chosen as Specialized Pharmacy Partner for RYPLAZIM® in Treating Plasminogen Deficiency Type 1 (PLGD-1)
Soleo Health, a prominent provider of specialized pharmacy services for rare and ultra-rare diseases, has been designated as a limited distribution specialty pharmacy partner for dispensing RYPLAZIM® (plasminogen, human-tvmh), developed…
GlycoMimetics Reveals Findings from Crucial Phase 3 Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (AML)
GlycoMimetics, Inc. (Nasdaq: GLYC), a biotechnology company specializing in advanced therapies for cancer and inflammatory conditions, has released the top-line results from its Phase 3 global pivotal trial of uproleselan…
Oregon Therapeutics & Lantern Pharma Team Up to Advance Novel Cancer Drug XCE853 with AI
Lantern Pharma Inc. (NASDAQ: LTRN), a prominent player in artificial intelligence (AI)-driven oncology drug discovery and development, has announced a strategic partnership with Oregon Therapeutics, a distinguished French biotechnology company.…
Kindeva Drug Delivery Expands Manufacturing Capabilities for Eco-Friendly Inhalers at UK Facility
Kindeva Drug Delivery, a prominent figure in the realm of drug-device combination products, has unveiled its plans to bolster its manufacturing capabilities with a second production line for pressurized metered-dose…
JELMYTO® Shows Impressive 86% Recurrence-Free Survival (RFS) at 24 Months Across Varied Patient Profiles: Insights from AUA 2024 Retrospective Analysis
UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological…